Megan Rice: Honored to Share First-Time Disclosure of a CD30 Dual-Payload ADC at AACR 2026

Megan Rice, Associate Principal Scientist at AstraZeneca, shared a post on LinkedIn:

“AACR2026 was nothing short of inspiring.

I was honored to share this first-time disclosure on behalf of the CD30 dual-payload ADC team, as part of the New Drugs on the Horizon series. This next-generation molecule was received with great enthusiasm, and we are looking forward to sharing further updates with the scientific community as it progresses through the clinic.

Many thanks to all at AACR who made this event possible, and to the CD30 dpADC team for bringing this molecule to life. ”